Slingshot Insights, a web community that connects investors with professional primary research tools and cost-shared expert interviews, will be conducting an expert call to talk about the trial success of SAGE Therapeutics Inc SAGE’s SAGE-547 on Friday.
The call will take a look at the results and setup for SAGE-547’s trial for the treatment of postpartum depression (PPD), trying to answer a simple question: does the drug have a place in the PPD space?
According to Slingshot Insights, this call is an important instance to better understand the extent to which the phase 2 study met its primary endpoint, significantly reducing the depression symptoms while yielding no reported adverse effects. However, they added, while the P value was very strong, the number of patients in the study was quite low. So, how significant are these results?
“Speaking to an expert will help determine how prevalent a treatment this may become versus the current, commonly used methods to treat PPD,” the firm went on to explain.
Interested? Join the call.
Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
